Cyient DLM Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0vcu54jbdc8oxidyvtj8upqq.pdf

Key Takeaways


The Margin Reset: What's Real and What's Not

Kulkarni: "Our Q4 margins are high due to a couple of one-off tailwinds that we received during the quarter... from a quarterly sustainable number, we should take out about 250 basis points from these numbers to see where we will land in future at these volumes."

The Defense Hole and the Rebuild

Kulkarni: "This is a business that is not at a level of stability where we can really predict. One deal can quickly change everything, right?"

US Operations: The Connecticut Option

Montalbano: "we have, I'd say, at least nine separate discussions, nine separate opportunities we're looking at that are just simply from our current clients that we are supporting in India today. Very eager to have learned that we now have a US option and so we're now quoting new products that really we didn't have access to before."

Portfolio Mix Shift

SegmentTrendCommentary
Aerospace▲ Strong growthUp 53% YoY, driven by top customers.
Defense▼ DecliningThe large Indian program ended; European defense clients are among the top five growth accounts heading into FY '26.
Medical▲ Growing shareNow 35% of the portfolio post-Altek; new medical logos are ramping to manufacturing faster than A&D programs.
Industrial▲ Growing share14% of portfolio post-Altek; also seeing faster new-logo ramp cycles.
Export vs India▬ ShiftingMix likely moving to 80-20 (rest of world vs India) as the large domestic program ends and most backlog to be serviced is export.
Montalbano: "Any one of these clients has the opportunity to be $50 million plus a year type of client for us as we build and scale the business with them."

Balance Sheet and Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA marginDouble-digit on a full-year basis; analyst range of 10–12% was not disputedFY '26
Operating cash flowPositiveFY '26
Order backlogReversal of the declining trendNo date given
Interest costReduction due to loan restructuring toward PCFC loansFY '26
Revenue mix80-20 rest of world vs IndiaFY '26
US operations revenueWins announced in coming quarter convert to revenueLatter part of FY '26
Large defense program renewalDepends on Ministry of Defense issuing an RFP; company well-positioned as incumbentNo timeline (external trigger)

Key Metrics

MetricQ4 FY25
Revenue₹428.1 cr, +18.3% YoY
Standalone revenue₹340.3 cr, -5.9% YoY
EBITDA₹57.4 cr, +50.9% YoY
EBITDA margin13.4%, +290 bps YoY; includes ~250 bps of one-off tailwinds from purchase price variance claims
PAT₹31 cr, +36.5% YoY; highest profit in 12 quarters since IPO
PAT margin7.3%, +96 bps YoY
Full-year revenue₹1,519.6 cr, +27.5% YoY
Full-year adjusted EBITDA₹145.2 cr, +30.8% YoY
Full-year adjusted EBITDA margin9.6%, +24 bps YoY; target was 10%
Full-year PAT₹74 cr, +21% YoY
Order backlog₹1,906 cr, declined QoQ; large Indian defense program concluded
Net working capital127 days, up from 120 days QoQ
Operating cash flow₹53 cr positive cash generated in Q4
Capacity utilization~60% overall; higher in Mysore, lower in other plants
New logos added6 in FY25; 5 of 6 are large multinational A-list companies
Top 5 client concentration~80% of revenue, expected to continue next year
Aerospace segment growth53% YoY, driven by top customers
Industry mix35% medical, 14% industrial; more balanced portfolio post-Altek acquisition
IPO proceeds utilized76.6%; ~₹115-120 cr remaining for incremental working capital